S01193 Summary:

BILL NOS01193
 
SAME ASSAME AS A07161
 
SPONSORPERSAUD
 
COSPNSRBORRELLO, CLEARE, COMRIE, PALUMBO, WEIK
 
MLTSPNSR
 
Add §2404-e, Pub Health L
 
Ensures ovarian cancer survivors have the right to access screenings for health conditions.
Go to top    

S01193 Actions:

BILL NOS01193
 
01/10/2023REFERRED TO WOMEN'S ISSUES
01/23/2023REPORTED AND COMMITTED TO FINANCE
05/09/20231ST REPORT CAL.829
05/10/20232ND REPORT CAL.
05/15/2023ADVANCED TO THIRD READING
06/01/2023PASSED SENATE
06/01/2023DELIVERED TO ASSEMBLY
06/01/2023referred to health
01/03/2024died in assembly
01/03/2024returned to senate
01/03/2024REFERRED TO WOMEN'S ISSUES
03/06/2024REPORTED AND COMMITTED TO FINANCE
Go to top

S01193 Committee Votes:

Go to top

S01193 Floor Votes:

There are no votes for this bill in this legislative session.
Go to top

S01193 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                          1193
 
                               2023-2024 Regular Sessions
 
                    IN SENATE
 
                                    January 10, 2023
                                       ___________
 
        Introduced  by Sens. PERSAUD, BORRELLO, CLEARE, COMRIE, PALUMBO, WEIK --
          read twice and ordered printed, and when printed to  be  committed  to
          the Committee on Women's Issues
 
        AN  ACT  to amend the public health law, in relation to ensuring ovarian
          cancer survivors have the right to access screenings for health condi-
          tions

          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
 
     1    Section  1.  The  public health law is amended by adding a new section
     2  2404-e to read as follows:
     3    § 2404-e. Ovarian cancer;  right  to  screenings.  No  person  with  a
     4  personal  history  of  ovarian cancer shall be denied genetic testing or
     5  genomic tumor profiling for inherited germline  mutations  and  acquired
     6  somatic  mutations,  respectively. In general, such testing shall not be
     7  subject to frequency caps or other limitations and  shall  include,  but
     8  not be limited to:
     9    (a) genetic mutations in BRCA1 and BRCA2 genes;
    10    (b) genetic mutations associated with Lynch syndrome;
    11    (c) rearrangement analysis of all coding exons associated with ovarian
    12  cancer; and
    13    (d)  additional  mutations  if medically necessary and appropriate, as
    14  determined by the health care professional treating the individual.
    15    § 2. This act shall take effect immediately.
 
 
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD02538-01-3
Go to top